Published • loading... • Updated
Setmelanotide successfully targeting extreme hunger in PWS trial
Summary by Prader-Willi Syndrome News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Setmelanotide successfully targeting extreme hunger in PWS trial
Treatment with setmelanotide helped reduce uncontrollable hunger, known as hyperphagia, and also eased anxiety in children and adults with obesity due to Prader-Willi syndrome (PWS). The Rhythm Pharmaceuticals‘ experimental injection therapy was also shown to reduce body fat and preserve lean mass in individuals with PWS. That’s according to six-month interim data from a one-year Phase 2 clinical trial (NCT06772597) that’s evaluating the therapy…
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
